Prometheus Biosciences, Inc.: insider trades · United States · SEC (Form 4)

About Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. was a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutic and companion diagnostic products for immune-mediated diseases. Before its acquisition, the company was listed in the United States on the NASDAQ market under the ticker RXDX and was headquartered in San Diego, California, a major biotechnology hub. Its model centered on precision medicine: using biomarker-driven patient stratification and targeted clinical development to improve the odds of therapeutic success in complex inflammatory and autoimmune disorders. Founded in 2016, Prometheus built its reputation around inflammatory bowel disease and broader immunology applications. Its lead asset was PRA023, a monoclonal antibody program aimed at ulcerative colitis, Crohn’s disease, and other immune-mediated conditions. The company’s strategy was not simply to develop a drug candidate, but to combine drug development with a companion diagnostic and a proprietary data-driven approach. That positioning made Prometheus stand out as a precision immunology platform rather than a conventional single-asset biotech, which is an important distinction for institutional investors assessing both upside potential and execution risk. From a competitive standpoint, Prometheus operated in a crowded and scientifically demanding field. Large pharmaceutical companies, specialty biotechs, and diagnostics players are all competing in immunology and inflammatory disease. Prometheus’ differentiator was its precision medicine framework and its effort to connect patient biology more directly to treatment selection. In theory, that approach could support better clinical outcomes, stronger differentiation, and potentially more efficient commercialization. In practice, however, it also meant the company carried the typical biotech risks: clinical trial uncertainty, regulatory hurdles, manufacturing complexity, and intense competition from alternative mechanisms of action. The most important recent development in the company’s history was Merck’s acquisition. In April 2023, Merck announced a definitive agreement to acquire Prometheus Biosciences, and the transaction was completed in June 2023. Merck described the deal as a way to expand its immunology franchise and add Prometheus’ precision-medicine capabilities and late-stage pipeline to its portfolio. The acquisition, valued at roughly $10.8 billion, effectively ended Prometheus’ life as an independent public company. As a result, for investors reviewing SEC Form 4 insider activity or legacy market data, it is important to note that Prometheus Biosciences no longer trades independently on NASDAQ in the United States; its assets were absorbed into Merck. For French-speaking investors, Prometheus remains a useful case study in how a focused clinical-stage biotech can create strategic value through a differentiated platform, strong scientific positioning, and acquisition appeal in a consolidating immunology market.